M&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts

In what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going shopping. Mid-cap American drugmakers, family-owned pharma groups, foundation-governed European players ...